Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024年1月13日 - 6:23AM
ビジネスワイヤ(英語)
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
focus on building an aesthetic portfolio of consumer brands, today
reported the grant of non-qualified stock options to purchase an
aggregate of 89,770 shares of Evolus and an aggregate of 82,730
restricted stock units (RSUs) of the company’s common stock to six
newly hired non-executive employees of the company. The awards were
approved by the compensation committee of the company’s board of
directors under Evolus’ 2023 Inducement Incentive Plan, with a
grant date of January 10, 2024, and a vesting commencement date of
January 7, 2024, as an inducement material to the new employees
entering into employment with Evolus in accordance with Nasdaq
Listing Rule 5635(c)(4).
The stock options have an exercise price of $10.68 per share,
the closing price of Evolus’ common stock on the date of grant. The
stock options have a 10-year term and vest over 4 years, with 25%
of the number of shares subject to the option vesting on each
annual anniversary of the vesting commencement date. The RSUs vest
25% on each annual anniversary of the vesting commencement date.
The awards are subject to the terms and conditions of the 2023
Inducement Incentive Plan and the terms and conditions of the stock
option agreement or RSU agreement, as applicable, covering the
grant, including requirements to remain continuously employed on
each vesting date.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a performance beauty company evolving
the aesthetic neurotoxin market for the next generation of beauty
consumers through its unique, customer-centric business model and
innovative digital platform. Our mission is to become a global,
multi-product aesthetics company based on our flagship product,
Jeuveau® (prabotulinumtoxinA-xvfs), globally licensed under the
brand name Nuceiva®. The product is manufactured in a
state-of-the-art facility using Hi-Pure™ technology. Evolus is
expanding its product portfolio having entered into a definitive
agreement to be the exclusive U.S. distributor of Evolysse™, a line
of five unique dermal fillers currently in late-stage development.
Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram
or Facebook.
Jeuveau®, Nuceiva®, and Evolysse™ are trademarks of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd. Estyme®
is a trademark of Symatese Aesthetics S.A.S.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240112200734/en/
Investors: Nareg Sagherian Vice
President, Head of Global Investor Relations and Corporate
Communications Tel: 248-202-9267 Email: ir@evolus.com
Media: Email:
media@evolus.com
Evolus (NASDAQ:EOLS)
過去 株価チャート
から 4 2024 まで 5 2024
Evolus (NASDAQ:EOLS)
過去 株価チャート
から 5 2023 まで 5 2024